S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Synthaverse SA
Investor Relations

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Waldemar Sierocki
Secretary of Supervisory Board & Member of Supervisory Board
No Bio Available
Mr. Mieczyslaw Starkowicz
President of the Management Board & CEO
No Bio Available
Radoslaw Wroblewski
Chief Financial Officer
No Bio Available
Mr. Jakub Winkler
Chief Organizational & Legal Officer and Member of the Management Board
No Bio Available
Ms. Katarzyna Krukowoska
Chief Accountant
No Bio Available

Contacts

Address
WOJ. LUBELSKIE
Lublin
Ul. Uniwersytecka 10
Contacts
+48815338221
synthaverse.pl